• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Omnicell Appoints Christine Mellon as Chief People Officer

    2/22/21 8:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email

    MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Christine Mellon has joined the company as Executive Vice President, Chief People Officer. Bringing more than 25 years of human resources, organizational, and cultural transformation leadership, Ms. Mellon will lead human resources functions, employee environments, and internal communications for Omnicell’s global operations.

    “As Omnicell continues to transform the pharmacy care delivery model to deliver on the vision of Autonomous Pharmacy, Christine’s role will be pivotal to shaping our people organization to support our business transformation to a technology-enabled services offering,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell.

    Ms. Mellon’s responsibilities include talent management, employee culture and engagement, diversity and inclusion, global rewards, business partnering, and real estate.

    Prior to joining Omnicell, Ms. Mellon served as Chief Human Resources Officer (CHRO) with CSG, where she transformed human resources into a valued strategic asset and led culture change efforts. She was previously Vice President, Human Capital Management for Oracle, where she consulted with North American CHRO clients, providing human capital strategic support, thought leadership, and HR technology guidance. Ms. Mellon has also served in HR leadership roles for Echostar and Cigna, among others.

    “I’m excited to join Omnicell in its mission to be the most trusted partner for medication management,” said Ms. Mellon. “I look forward to building a dynamic global team committed to delivering the technology, intelligence, and ‘as a service’ offerings to help our customers navigate the evolving complexities of medication management.”

    About Omnicell

    Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

    OMCL-G

    Get the next $OMCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omnicell upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

      5/14/25 8:50:33 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by BofA Securities with a new price target

      BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

      10/31/24 7:49:39 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Barclays with a new price target

      Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

      8/2/24 7:36:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology